| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 3841 | 2015 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology 26 (7), 1148-1159, 2008 | 2472 | 2008 |
| Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ... New England Journal of Medicine 385 (12), 1091-1103, 2021 | 1706 | 2021 |
| Organoid cultures derived from patients with advanced prostate cancer D Gao, I Vela, A Sboner, PJ Iaquinta, WR Karthaus, A Gopalan, ... Cell 159 (1), 176-187, 2014 | 1546 | 2014 |
| Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016 | 1436 | 2016 |
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ... The Lancet 375 (9724), 1437-1446, 2010 | 1322 | 2010 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 880* | 2018 |
| Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial TK Choueiri, S Halabi, BL Sanford, O Hahn, MD Michaelson, MK Walsh, ... Journal of Clinical Oncology 35 (6), 591-597, 2017 | 831 | 2017 |
| Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ... JAMA oncology 5 (4), 471-478, 2019 | 605 | 2019 |
| Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ... JCO precision oncology 1, 1-16, 2017 | 557 | 2017 |
| Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ... Journal of Clinical Oncology 28 (9), 1496-1501, 2010 | 540 | 2010 |
| Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate … WK Kelly, S Halabi, M Carducci, D George, JF Mahoney, WM Stadler, ... Journal of Clinical Oncology 30 (13), 1534-1540, 2012 | 514 | 2012 |
| Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer S Halabi, CY Lin, WK Kelly, KS Fizazi, JW Moul, EB Kaplan, MJ Morris, ... Journal of Clinical Oncology 32 (7), 671-677, 2014 | 507 | 2014 |
| Phase II study of lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer ST Tagawa, MI Milowsky, M Morris, S Vallabhajosula, P Christos, ... Clinical cancer research 19 (18), 5182-5191, 2013 | 496 | 2013 |
| Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ... Journal of clinical oncology 34 (14), 1652-1659, 2016 | 448 | 2016 |
| Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free … TK Choueiri, C Hessel, S Halabi, B Sanford, MD Michaelson, O Hahn, ... European journal of cancer 94, 115-125, 2018 | 415 | 2018 |
| Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer SM Larson, M Morris, I Gunther, B Beattie, JL Humm, TA Akhurst, RD Finn, ... Journal of Nuclear Medicine 45 (3), 366-373, 2004 | 414 | 2004 |
| Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ... Cell 185 (3), 563-575. e11, 2022 | 382 | 2022 |
| Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer DJ Gallagher, MM Gaudet, P Pal, T Kirchhoff, L Balistreri, K Vora, J Bhatia, ... Clinical cancer research 16 (7), 2115-2121, 2010 | 365 | 2010 |
| A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer … KJ Pienta, MA Gorin, SP Rowe, PR Carroll, F Pouliot, S Probst, ... The Journal of urology 206 (1), 52-61, 2021 | 300 | 2021 |
Susan Halabi, PhD, FSCT, FASA, FAS...Duke UniversityVerified email at duke.edu
